October 11, 2018
Source: Oncoimmunology. 2018 Oct 11;7(12):e1526250. doi: 10.1080/2162402X.2018.1526250. eCollection 2018.
Authors: M. Smith, E. García-Martínez, M.R. Pitter, J. Fucikova, R. Spisek, L. Zitvogel, G. Kroemer, L. Galluzzi
Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.